In addition to sclerostin inhibitor (romosozumab), another new agent (abaloparatide) is also in phase III trials. Abaloparatide is an anabolic, parathyroid hormone-related protein (PTHrP) analog drug being developed by Radius Health for the osteoposis market and is now in phase III clinical trials…
